





Table. Demographics, Safety, and Efficacy for Patients Receiving BGB-3111 in Combination With BGB-A317

	CLL	MCL	All DLBCL	FL, MZL, & WM	Transformed (Richter's & Transformed FL)	All Pts		
	Cohorts 1 & 2 (N=5)	Cohort 2 (N=2)	Cohorts 1 & 2 (N=5)	Cohorts 1 & 2 (N=8)	Cohorts 1 & 2 (N=5)	Cohort 1 (N=15)	Cohort 2 (N=10)	Cohorts 1 & 2 (N=25)
<b>Demographics</b>								
Median (range) age, y	66 (47-76)	63 (62-64)	62 (27-65)	60.5 (55-71)	64 (51-71)	62 (27-76)	62.5 (47-68)	62 (27-76)
<b>ECOG PS, N (%)</b>								
0	2 (40)	1 (50)	1 (20)	5 (62.5)	1 (20)	6 (40)	4 (40)	10 (40)
1	0	0	3 (60)	3 (37.5)	4 (80)	7 (46.7)	3 (30)	10 (40)
2	3 (60)	0	1 (20)	0	0	2 (13.3)	2 (20)	4 (16)
3	0	1 (50)	0	0	0	0	1 (10)	1 (4)
Median no. of prior therapies (range)	5 (1-6)	2 (1-3)	4 (2-6)	3 (1-6)	5 (3-6)	5 (1-6)	2.5 (1-6)	4 (1-6)
Median mo follow-up (range)	1.7 (1.6-3.1)	2.8 (0.4-5.3)	2.8 (1.1-8.5)	4.6 (1.6-10.6)	6.7 (0.8-10.7)	2.8 (0.8-10.7)	3 (0.4-7.9)	2.8 (0.4-10.7)
<b>Safety, N (%)</b>								
Any AE	5 (100)	1 (50)	5 (100)	7 (87.5)	5 (100)	15 (100)	8 (80)	23 (92)
Grade ≥3 AE	3 (60)	1 (50)	3 (60)	4 (50)	4 (80)	8 (53.3)	7 (70)	15 (60)
Serious AE	1 (20)	1 (50)	5 (100)	3 (37.5)	3 (60)	7 (46.7)	6 (60)	13 (52)
AEs leading to Rx discontinuation	1 (20)	0	1 (20)	3 (37.5)	1 (20)	3 (20)	3 (30)	6 (24)
Fatal AE	0	0	1 (20)	0	0	0	1 (10)	1 (4.0)
<b>Efficacy (best response), N (%)</b>								
ORR	0	0	1 (20)	3 (50)	2 (40)	3 (25)	3 (37.5)	6 (30)
CR	0	0	1 (20)	1 (16.7)	0	2 (16.7)	0	2 (10)
VGPR	-	-	-	1	-	-	1	1
PR	0	0	0	0	2 (40)	1 (8.3)	1 (12.5)	2 (10)
MR	-	-	-	1	-	-	1	1
SD	0	1 (50)	2 (40)	2 (33.3)	1 (20)	4 (33.3)	2 (25)	6 (30)
PD	1 (50)	1 (50)	2 (40)	0	2 (40)	4 (33.3)	2 (25)	6 (30)
Not evaluable	1 (50)	0	0	1 (16.7)	0	1 (8.3)	1 (12.5)	2 (10)

AE, treatment-emergent adverse event; CR, complete response; ORR, objective response rate; PD, progressive disease; PR, partial response; Rx, treatment; SD, stable disease; ECOG PS, Eastern Cooperative Oncology Group Performance Status; RR, response rate; VGPR, very good partial response